Last reviewed · How we verify
Placebo matched to ocrelizumab
Placebo matched to ocrelizumab is a Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development.
This is a placebo control arm matched to ocrelizumab, the active comparator, and contains no pharmacologically active ingredient.
At a glance
| Generic name | Placebo matched to ocrelizumab |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo matched to ocrelizumab is an inert formulation designed to match the appearance, administration route, and schedule of ocrelizumab (an anti-CD20 monoclonal antibody) for blinded clinical trial purposes. It allows for comparison of ocrelizumab's efficacy and safety against a control without active drug effect. The matching ensures trial integrity by preventing bias from differences in injection appearance or frequency.
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (PHASE3)
- A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PHASE3)
- A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) (PHASE3)
- A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis (PHASE2)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis (PHASE3)
- A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matched to ocrelizumab CI brief — competitive landscape report
- Placebo matched to ocrelizumab updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Placebo matched to ocrelizumab
What is Placebo matched to ocrelizumab?
How does Placebo matched to ocrelizumab work?
Who makes Placebo matched to ocrelizumab?
What development phase is Placebo matched to ocrelizumab in?
Related
- Manufacturer: Hoffmann-La Roche — full pipeline
- Compare: Placebo matched to ocrelizumab vs similar drugs
- Pricing: Placebo matched to ocrelizumab cost, discount & access